

# Florian Schuetz

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3606690/florian-schuetz-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

56  
papers

1,235  
citations

20  
h-index

34  
g-index

57  
ext. papers

1,407  
ext. citations

4  
avg, IF

3.7  
L-index

| #  | Paper  | IF  | Citations |
|----|--|-----|-----------|
| 56 | Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial.. <i>Journal of Medical Internet Research</i> , <b>2022</b> , 24, e16128                          | 7.6 | 0         |
| 55 | CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,  | 3.6 | 5         |
| 54 | Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. <i>European Journal of Cancer</i> , <b>2021</b> , 154, 128-137  | 7.5 | 5         |
| 53 | Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 179, 643-652  | 4.4 |           |
| 52 | Exam preparatory course for the 2nd part of the German medical examination in obstetrics and gynecology - a potential tool for the recruitment of new residents during the occupational decision process before the practical year?. <i>BMC Medical Education</i> , <b>2019</b> , 19, 24             | 3.3 | 2         |
| 51 | Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells. <i>Cancers</i> , <b>2019</b> , 11,  | 6.6 | 4         |
| 50 | An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study. <i>Journal of Medical Internet Research</i> , <b>2019</b> , 21, e10004 | 7.6 | 16        |
| 49 | Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1. <i>Cancer Immunology, Immunotherapy</i> , <b>2017</b> , 66, 593-603  | 7.4 | 16        |
| 48 | Impact of reproductive factors on breast cancer subtypes in postmenopausal women: a retrospective single-center study. <i>Archives of Gynecology and Obstetrics</i> , <b>2017</b> , 295, 971-978   | 2.5 | 2         |
| 47 | PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis. <i>Oncology Letters</i> , <b>2017</b> , 13, 2847-2851   | 2.6 | 8         |
| 46 | Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry. <i>Oncotarget</i> , <b>2017</b> , 8, 51416-51428   | 3.3 | 7         |
| 45 | Influence of Paclitaxel and Heparin on Vitality, Proliferation and Cytokine Production of Endometrial Cancer Cells. <i>Geburtshilfe Und Frauenheilkunde</i> , <b>2017</b> , 77, 1104-1110  | 2   | 2         |
| 44 | Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 549-558  | 3.9 | 10        |
| 43 | Analysis of everolimus starting dose as prognostic marker in HR+ mBC patients treated with everolimus (EVE) + exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1061-1061                        | 2.2 | 2         |
| 42 | Parity improves anti-tumor immunity in breast cancer patients. <i>Oncotarget</i> , <b>2017</b> , 8, 104981-104991  | 3.3 | 3         |
| 41 | Median progression free survival (PFS) for patients treated with everolimus (EVE) + exemestane (EXE) for HR+ mBC in routine clinical practice: Results of the 3rd interim analysis of the non-interventional trial BRAWO.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e12547-e12547     | 2.2 |           |
| 40 | Exam preparation course in obstetrics and gynecology for the German Medical State Examination: proof of concept and implications for the recruitment of future residents. <i>Archives of Gynecology and Obstetrics</i> , <b>2016</b> , 294, 1235-1241  | 2.5 | 3         |

|    |   |     |    |
|----|---|-----|----|
| 39 | Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. <i>Breast Care</i> , <b>2016</b> , 11, 102-7  | 2.4 | 17 |
| 38 | Breast cancer presentation and therapy in migrant versus native German patients: contrasting and convergent data of a retrospective monocentric study. <i>Archives of Gynecology and Obstetrics</i> , <b>2016</b> , 294, 145-52                                   | 2.5 | 3  |
| 37 | Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 757-66 | 3.1 | 14 |
| 36 | Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients. <i>OncolImmunology</i> , <b>2016</b> , 5, e1057387   | 7.2 | 32 |
| 35 | Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , <b>2016</b> , 294, 123-9  | 2.5 | 5  |
| 34 | Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial. <i>OncoTargets and Therapy</i> , <b>2016</b> , 9, 4173-80   | 4.4 | 6  |
| 33 | Do Contralateral Prophylactic Mastectomies Help Patients?. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4191   | 2.2 | 1  |
| 32 | Predictors of early poor aesthetic outcome after breast-conserving surgery in patients with breast cancer: initial results of a prospective cohort study at a single institution. <i>Journal of Surgical Oncology</i> , <b>2014</b> , 110, 801-6                  | 2.8 | 27 |
| 31 | Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 148, 143-51  | 4.4 | 34 |
| 30 | Side effects of bone-targeted therapies in advanced breast cancer. <i>Breast Care</i> , <b>2014</b> , 9, 332-6  | 2.4 | 25 |
| 29 | Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer. <i>Anti-Cancer Drugs</i> , <b>2014</b> , 25, 219-24  | 2.4 | 23 |
| 28 | Adoptive immunotherapy of metastatic breast cancer: present and future. <i>Cancer and Metastasis Reviews</i> , <b>2014</b> , 33, 309-20   | 9.6 | 16 |
| 27 | Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer. <i>Anticancer Research</i> , <b>2014</b> , 34, 6609-15   | 2.3 | 30 |
| 26 | Breast cancer mastectomy trends between 2006 and 2010: association with magnetic resonance imaging, immediate breast reconstruction, and hospital volume. <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 3839-46  | 3.1 | 16 |
| 25 | Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial. <i>Cancer Immunology, Immunotherapy</i> , <b>2013</b> , 62, 1053-60  | 7.4 | 37 |
| 24 | Interobserver reliability of automated breast volume scanner (ABVS) interpretation and agreement of ABVS findings with hand held breast ultrasound (HHUS), mammography and pathology results. <i>European Journal of Radiology</i> , <b>2013</b> , 82, e332-6     | 4.7 | 54 |
| 23 | Prognostic value of disseminated tumor cells in the bone marrow of patients with operable primary breast cancer: a long-term follow-up study. <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 1865-71  | 3.1 | 21 |
| 22 | Bone marrow microenvironment in cancer patients: immunological aspects and clinical implications. <i>Cancer and Metastasis Reviews</i> , <b>2013</b> , 32, 163-78   | 9.6 | 15 |

|    |  |      |     |
|----|--|------|-----|
| 21 | Prediction of underestimated invasiveness in patients with ductal carcinoma in situ of the breast on percutaneous biopsy as rationale for recommending concurrent sentinel lymph node biopsy. <i>Breast</i> , <b>2013</b> , 22, 537-42 | 3.6  | 38  |
| 20 | B cell-regulated immune responses in tumor models and cancer patients. <i>Onc Immunology</i> , <b>2013</b> , 2, e25443   |      | 91  |
| 19 | HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients. <i>Onc Immunology</i> , <b>2013</b> , 2, e24962  | 7.2  | 20  |
| 18 | Objective assessment of aesthetic outcome after breast conserving therapy: subjective third party panel rating and objective BCCT.core software evaluation. <i>Breast</i> , <b>2012</b> , 21, 61-5                                     | 3.6  | 28  |
| 17 | Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. <i>Cancer Immunology, Immunotherapy</i> , <b>2012</b> , 61, 353-62   | 7.4  | 166 |
| 16 | Do reexcisions impair aesthetic outcome in breast conservation surgery? Exploratory analysis of a prospective cohort study. <i>Annals of Surgical Oncology</i> , <b>2012</b> , 19, 541-7   | 3.1  | 40  |
| 15 | Neoadjuvant epirubicin, gemcitabine, and docetaxel for primary breast cancer: Survival and prognostic factors in two consecutive neoadjuvant phase I/II trials.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1096-1096     | 2.2  |     |
| 14 | Circulating tumor cells in metastatic breast cancer: Are they a strong and independent predictor of poor progression-free and overall survival?. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1090-1090                     | 2.2  |     |
| 13 | Intraoperative bone marrow puncture in breast cancer patients: prospective assessment of adverse side-effects. <i>Breast</i> , <b>2011</b> , 20, 62-5  | 3.6  | 5   |
| 12 | Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients. <i>Cancer Immunology, Immunotherapy</i> , <b>2011</b> , 60, 401-11                              | 7.4  | 4   |
| 11 | Therapeutic effects of metformin in breast cancer: involvement of the immune system?. <i>Cancer Immunology, Immunotherapy</i> , <b>2011</b> , 60, 1221-5   | 7.4  | 15  |
| 10 | Adjuvant Systemic Therapy of Breast Cancer. <i>Breast Care</i> , <b>2011</b> , 6, 179-183  | 2.4  | 4   |
| 9  | Effects of distant metastasis and peripheral CA 15-3 on the induction of spontaneous T cell responses in breast cancer patients. <i>Cancer Immunology, Immunotherapy</i> , <b>2010</b> , 59, 479-86                                    | 7.4  | 6   |
| 8  | Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. <i>Cancer Research</i> , <b>2009</b> , 69, 8420-8                                      | 10.1 | 53  |
| 7  | Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study. <i>Cancer Immunology, Immunotherapy</i> , <b>2009</b> , 58, 887-900                                  | 7.4  | 42  |
| 6  | Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. <i>American Journal of Obstetrics and Gynecology</i> , <b>2007</b> , 196, 342.e1-9      | 6.4  | 29  |
| 5  | Bevacizumab in the Treatment of Metastatic Breast Cancer. <i>Breast Care</i> , <b>2007</b> , 2, 82-88  | 2.4  | 4   |
| 4  | Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. <i>Anti-Cancer Drugs</i> , <b>2007</b> , 18, 477-85                                 | 2.4  | 66  |

|   |  |     |     |
|---|--|-----|-----|
| 3 | Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study. <i>Anti-Cancer Drugs</i> , <b>2007</b> , 18, 963-8  | 2.4 | 23  |
| 2 | Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 1839-45                        | 2.2 | 129 |
| 1 | Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial. <i>Anti-Cancer Drugs</i> , <b>2005</b> , 16, 1023-8 | 2.4 | 11  |